Histopathological Study on The Effect of Neuregulin-1 Against Cardiotoxicity Induced By Trastuzumab in Adult Mice

Histopathological Study on The Effect of Neuregulin-1 Against Cardiotoxicity Induced By Trastuzumab in Adult Mice

Objective: This work carried out to investigate the potential therapeutic effect of Neuregulin-1 against cardiotoxicity induced by trastuzumab in male mice. Materials and Methods: Forty five adult male and female mice (weighing 35-50 gm) were divided into 3 groups randomly, each group contai...

Full description

Bibliographic Details
Main Authors:	yousuf gays majeed, mustafa ghazi al-abbassi, ghaith ali jasim al-zubaidy
Format:	Article
Language:	English
Published:	College of Pharmacy / Mustansiriyah University 2018-12-01
Series:	Al-Mustansiriyah Journal of Pharmaceutical Sciences
Subjects:	Neuregulin-1, Cardiotoxicity, Trastuzumab, TNF-α, IL-1β.
Online Access:	https://ajps.uomustansiriyah.edu.iq/index.php/AJPS/article/view/477

Similar Items

Trastuzumab and cardiotoxicity
by: Petra Sertić, et al.
Published: (2024-01-01)

Compensatory role of neuregulin-1 in diabetic cardiomyopathy
by: Yoshinori Mikami, et al.
Published: (2023-11-01)

Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01)

Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023-02-01)

Mechanisms of trastuzumab induced cardiotoxicity – is exercise a potential treatment?
by: Holden Eaton, et al.
Published: (2023-04-01)

Chemotherapy-induced cardiotoxic effect in breast cancer patients treated with trastuzumab (Herceptin) by MRI
by: Mohamed Aboulfotouh Mourad, et al.
Published: (2023-12-01)

Early cardiotoxicity after adjuvant concomitant treatment with radiotherapy and trastuzumab in patients with breast cancer
by: Marinko Tanja, et al.
Published: (2018-02-01)

Trastuzumab-Related Cardiotoxicity in Adjuvant Setting: A Real-World Scenario
by: Sarita Shrivastva, et al.
Published: (2023-07-01)

Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis
by: Kyriakos Goulas, et al.
Published: (2023-07-01)

Structural and Electrophysiological Changes in a Model of Cardiotoxicity Induced by Anthracycline Combined With Trastuzumab
by: Claudia Altomare, et al.
Published: (2021-04-01)

Interventions for Preventing Cardiotoxicity in Breast Cancer Patients Receiving Trastuzumab: A Systemic Review and Bayesian Network Meta-Analysis
by: Xinyi Li, et al.
Published: (2021-08-01)

Neuregulins Response to Exercise: a Mini Review
by: Abbass Ghanbari-Niaki
Published: (2016-04-01)

Cardiotoxicity: Importance of biomarkers
by: Kostadinović Jelena, et al.
Published: (2023-01-01)

Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01)

Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)

Trastuzumab and ECG Changes Dilemma
by: Azin Alizadehasl, et al.
Published: (2023-04-01)

Interventions for prevention and treatment of trastuzumab-induced cardiotoxicity: an umbrella review of systematic reviews and meta-analyses
by: Yunfang Wang, et al.
Published: (2024-12-01)

Prevalence of Cardiotoxicity Secondary to Trastuzumab in Patients with HER-2-Positive Breast Cancer in Southeast Mexico
by: Luz I. Pascual-Mathey, et al.
Published: (2024-09-01)

Cardiotoxicity Associated with Trastuzumab Therapy in Taiwan: A Single Medical Center's 5-Year Experience
by: Che-Ming Chang, et al.
Published: (2015-06-01)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
by: Mengmeng Lin, et al.
Published: (2022-01-01)

Noncoding RNA-associated competing endogenous RNA networks in trastuzumab-induced cardiotoxicity
by: Suifen Xie, et al.
Published: (2024-09-01)

Role of Exogenous Neuregulin-1 as a Therapeutic Agent in Focal Epilepsy [Letter]
by: Gul O, et al.
Published: (2024-05-01)

Plasma Level’s of Neuregulin-1 in Healthy People
by: K. A. Zhbanov, et al.
Published: (2022-01-01)

Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer
by: Iljovska Marina, et al.
Published: (2023-01-01)

Exploring an novel diagnostic gene of trastuzumab-induced cardiotoxicity based on bioinformatics and machine learning
by: Jixiang Pei, et al.
Published: (2024-12-01)

Association of Neuregulin Levels and Neuregulin-1 Polymorphism with Short-term Morbidities in Preterm Neonates
by: Bugis Lubis, et al.
Published: (2021-10-01)

Potential Ameliorating Role of Spironolactone in Trastuzumab-induced Cardiotoxicity: A Narrative Review
by: Amir Ghabousian, et al.
Published: (2021-11-01)

Acetylcholinesterase inhibition protects against trastuzumab-induced cardiotoxicity through reducing multiple programmed cell death pathways
by: Thawatchai Khuanjing, et al.
Published: (2023-09-01)

Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome
by: Iacopo Fabiani, et al.
Published: (2020-08-01)

Cardiotoxicity after Additional Administration of Pertuzumab following Long-Term Trastuzumab: Report of 2 Cases
by: Mayuko Ito, et al.
Published: (2021-02-01)

Neuregulin-1 Protects Neuronal Cells Against Damage due to CoCl-Induced Hypoxia by Suppressing Hypoxia-Inducible Factor-1α and P53 in SH-SY5Y Cells
by: Seung-Yeon Yoo, et al.
Published: (2019-11-01)

Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
by: Anna Vaynrub, et al.
Published: (2024-10-01)

Early detection of anthracycline‐ and trastuzumab‐induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters
by: Belén Díaz‐Antón, et al.
Published: (2022-04-01)

Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
by: Santino Minichillo, et al.
Published: (2017-11-01)

Neuregulin-1 signaling regulates cytokines and chemokines expression and secretion in granulosa cell
by: Saswati Banerjee, et al.
Published: (2022-07-01)

Neuregulin-1 Promotes Myocardial Angiogenesis in the Rat Model of Diabetic Cardiomyopathy
by: Chun Gui, et al.
Published: (2018-05-01)

Is neuregulin-1 (NRG-1) a potential blood biomarker linking depression to obesity? A case-control study
by: Heba Ahmed Abdelaziz, et al.
Published: (2023-09-01)

Protein Phosphatase-1 Regulates Expression of Neuregulin-1
by: Tatiana Ammosova, et al.
Published: (2016-12-01)

Cardioprotection From Cardiotoxicity
by: Guilherme H. Oliveira, MD, MBA
Published: (2019-09-01)

NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients
by: Isabel Blancas, et al.
Published: (2020-12-01)